Jesper Lindhardsen

Medicin og biovidenskab

1. Cohort Studies 100%
2. Atrial Fibrillation 54%
3. Myocardial Infarction 52%
4. Psoriasis 50%
5. Anti-Inflammatory Agents 34%
6. Rheumatoid Arthritis 28%
7. Thromboembolism 27%
8. Stroke 26%
9. Denmark 23%
10. Inflammatory Bowel Diseases 21%
11. Cardiovascular Diseases 20%
12. Pharmaceutical Preparations 18%
13. Systemic Lupus Erythematosus 17%
14. Mortality 16%
15. Incidence 16%
16. Hemorrhage 14%
17. Hospitalization 14%
18. Morbidity 12%
19. Registries 12%
20. Confidence Intervals 12%
21. Population 11%
22. Granulomatosis with Polyangiitis 10%
23. Guidelines 10%
24. Lupus Nephritis 10%
25. Hormone Replacement Therapy 9%
26. Proton Pump Inhibitors 9%
27. Diabetes Mellitus 9%
28. Heart Failure 9%
29. Tumor Necrosis Factor Inhibitors 9%
30. Venous Thromboembolism 9%
31. Rheumatic Diseases 7%
32. Aspirin 7%
33. Roflumilast 7%
34. Risk Management 7%
35. Therapeutics 7%
36. Drug Therapy 7%
37. Observational Studies 7%
38. Chronic Disease 6%
39. Antirheumatic Agents 6%
40. Clopidogrel 6%
41. Safety 5%
42. Giant Cell Arteritis 5%
43. Out-of-Hospital Cardiac Arrest 5%
44. Arthritis 5%
45. Inflammation 5%
46. Psoriatic Arthritis 5%
47. Secondary Prevention 5%
48. Proportional Hazards Models 5%
49. Aortic Valve Insufficiency 5%
50. Vitamin K 5%